Get the Stockscreener App
0.2139
18.64%
0.0336
After Hours:
.22
0.0061
+2.85%
Can-Fite Biopharma Ltd ADR stock is traded at $0.2139, with a volume of 174.78M.
It is up +18.64% in the last 24 hours and down -36.34% over the past month.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$0.1803
Open:
$0.2707
24h Volume:
174.78M
Relative Volume:
19.76
Market Cap:
$3.65M
Revenue:
$743.00K
Net Income/Loss:
$-7.63M
P/E Ratio:
-0.0713
EPS:
-3
Net Cash Flow:
-
1W Performance:
-15.15%
1M Performance:
-36.34%
6M Performance:
-79.23%
1Y Performance:
-85.97%
1-Day Range:
$0.21
$0.2735
1-Week Range:
$0.17
$0.2735
52-Week Range:
$0.17
$2.33
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADR
Sector
Industry
Phone
972 3 924 1114
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.2139 | 3.08M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-17 | Initiated | Maxim Group | Buy |
| Oct-19-16 | Resumed | ROTH Capital | Buy |
| Aug-29-16 | Resumed | Rodman & Renshaw | Buy |
| Nov-30-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-31-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-30-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-29-14 | Reiterated | ROTH Capital | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
View All
Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction By Investing.com - Investing.com South Africa
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction - Investing.com India
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split By Investing.com - Investing.com South Africa
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com India
Can-Fite BioPharma announces 1-for-3,000 reverse stock split - Investing.com
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - GlobeNewswire Inc.
Can Can Fite Biopharma Ltd Sponsored ADR stock ride next bull market cycleMarket Rally & Community Verified Trade Signals - Улправда
EBITDA per share of Can-Fite BioPharma Ltd. Sponsored ADR – AMEX:CANF - TradingView — Track All Markets
AST SpaceMobile Inc (ASTS) can make a big difference with a little luck - setenews.com
Can Can Fite Biopharma Ltd Sponsored ADR stock survive global slowdown2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock sustain breakout momentum2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock test all time highsMarket Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Is Can Fite Biopharma Ltd Sponsored ADR stock positioned for secular growth2025 Key Lessons & Growth Focused Entry Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
An analyst sees good growth prospects for Can-Fite Biopharma Ltd ADR (CANF) - Setenews
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference - The Manila Times
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - Sahm
Will Can Fite Biopharma Ltd Sponsored ADR stock beat revenue estimatesQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong analyst pickJuly 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
Can Can Fite Biopharma Ltd Sponsored ADR stock expand revenue streams - newser.com
Take off with Santech Holdings Ltd. ADR (STEC): Get ready for trading - Setenews
How does Can-Fite Biopharma Ltd ADR (CANF) change from a tortoise to a hare? - Setenews
Can-Fite BioPharma (NYSE American: CANF) reports 9-year Namodenoson response in HCC - Stock Titan
Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):